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Abstract Hyaluronic acid (HA) is a polysaccharide
found in the extracellular matrix of vertebrate epithelial,
neural and connective tissues. Due to the high moisture
retention, biocompatibility and viscoelasticity properties of
this polymer, HA has become an important component of
major pharmaceutical, biomedical and cosmetic products
with high commercial value worldwide. Currently, large
scale production of HA involves extraction from animal
tissues as well as the use of bacterial expression systems in
Streptococci. However, due to concerns over safety,
alternative sources of HA have been pursued which include
the use of endotoxin-free microorganisms such as Bacilli
and Escherichia coli. In this review, we explore current
knowledge of biosynthetic enzymes that produce HA, how
these systems have been used commercially to produce HA
and how the challenges of producing HA cheaply and
safely are being addressed.
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Introduction
Hyaluronic acid (HA) is a linear glycosaminoglycan
polymer commonly found in the extracellular matrix of
vertebrate epithelial, neural and connective tissues. It is
also involved in many signalling pathways including those
involved in embryonic development, wound healing,
inflammation and cancer (Stern et al. 2006). HA is also a
component of the extracellular capsule formed by some
microorganisms, such as Streptococcus, that serves not
only for adherence and protection, but also as a molecular
mimicry to evade host’s immune system during its infec-
tion process (Wessels et al. 1991).
Due to its high moisture retention and viscoelasticity
properties, numerous biomedical, pharmaceutical and cos-
metic products have been developed with the use of HA.
Depending on the type and function of the HA-based end-
product, the starting material is dependent on the chain
length of HA to define its application. For example, HA
with high molecular weight (greater than 10 kDa) is
desirable for products used in ophthalmology, orthopaedic,
cosmetics and tissue engineering (Allison and Grande-Al-
len 2006; Fagien and Cassuto 2012; Kogan et al. 2007)
whereas HA with low molecular weight (about 5 kDa and
below) are useful for producing substances that promote
angiogenesis, inhibit tumour progression or induce
expression of pro-inflammatory mediators (Jagannath and
Ramachandran 2010; Tammi et al. 2008).
Currently there are two production processes employed
to obtain HA polymer in commercial quantities: extraction
from animal tissues, typically rooster combs, or more
recently though the application of bacterial expression
systems in Streptococcus. Both approaches have faced
considerable concerns over the safety of using biomedical
products derived either from animal products or
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Streptococcus, a known pathogen that produces several
endotoxins (Liu et al. 2011). To address these issues, two
alternatives have been considered: (a) to generate HA via
cell-free system, and thus avoid contamination of endo-
toxins and reduce cost of purification and/or (b) genetically
engineer different microorganisms that do not produce
endotoxins (Widner et al. 2005; Yu and Stephanopoulos
2008). In this review, we explore current knowledge of
biosynthetic enzymes that produce HA, how these systems
have been used commercially to produce HA and discuss
how the challenges of producing HA safely and cheaply are
being addressed.
Hyaluronic acid
Hyaluronic acid (HA), also known as hyaluronan, is a
linear glycosaminoglycan (GAG) composed of repeating
disaccharides of b4-glucuronic acid (GlcUA)-b3-N-
acetylglucosamine (GlcNAc) (Fig. 1). HA was first iso-
lated and identified from the vitreous body of bovine’s eye
(Meyer and Palmer 1934). Eventually this polysaccharide
was found to be ubiquitously distributed in many parts of
vertebrate tissues (brain, umbilical cord, synovial fluid in
between joints, skin, rooster comb, neural tissues and
epithelium) with differing concentrations and molecular
weights (Fraser et al. 1997).
HA is naturally negatively charged (due to the car-
boxylate groups) and this allows it to bind to a large
amount of water forming a highly viscous gel. This anionic
gel-like polymer offers not only lubrication for the joints
but also acts as a shock-absorber for the surrounding tissues
(Fraser et al. 1997). Moreover, it is non-immunogenic as it
does not initiate immune response in humans and other
vertebrates (Schiraldi et al. 2010). Due to its unique bio-
compatibility and viscoelastic properties, it lends itself to
biomedical applications such as drug delivery, ophthalmic
surgery, osteoarthritis treatment and tissue engineering
(DeAngelis 2012). It is also used in cosmetics applications,
notably as dermal fillers and moisturizers (Fagien and
Cassuto 2012). HA is recognised as a signalling molecule
involved in many mammalian biological processes and
plays critical roles in several disease causing events such as
inflammation, tumorigenesis and abnormal immune func-
tion (Cooper et al. 2008; Stern et al. 2006; Tammi et al.
2008). As HA does not initiate an immune response, bac-
teria such as Streptococcus zooepidemicus synthesise HA
as a means to encapsulate their cells and exhibit molecular
mimicry to escape detection from the host’s immune sys-
tem (Boyce et al. 2000; Wessels et al. 1991). HA is also
naturally produced by other pathogenic bacteria including
Streptococcus pyogenes, Streptococcus uberis, Pasteurella
multocida and Cryptococcus neoformans (Blank et al.
2008; DeAngelis et al. 1993, 1998; Jong et al. 2007).
Biosynthesis of HA
has operon in Streptococci
The has operon was first discovered in early 1990s when a
gene encoding the enzyme responsible for HA synthesis,
denoted as HA synthase or HAS, was identified from
Group A Streptococcus (S. pyogenes) (DeAngelis et al.
1993). This gene is part of an operon containing the hasA
gene that encodes HA synthase, hasB gene that encodes
UDP-glucose dehydrogenase, and the hasC gene that
encodes UDP-glucose pyrophosphorylase (Crater et al.
1995; Dougherty and van de Rijn 1993). The has operon in
other streptococci, such as S. zooepidemicus, contain two
additional genes, hasD and hasE that encode a bi-func-
tional enzyme (acetyltransferase and pyrophosphorylase)
and phosphoglucoisomerase respectively, allowing HA to
be synthesised by additional metabolic pathway. The
addition of these two genes to the has operon are thought to
have been facilitated by intragenomic gene duplication
together with frequent homologous recombination (Blank
et al. 2008).
Biosynthetic pathway
Most studies of HA biosynthesis in prokaryotes have
focused on S. zooepidemicus, which uses two distinct
pathways to synthesise HA precursors (Chong et al. 2005;
DeAngelis 1996). Biosynthesis of HA begins with the
phosphorylation of glucose by hexokinase to produce the
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Fig. 1 Structure of a hyaluronic acid monomer. HA consists of
glucuronic acid and N-acetylglucosamine that can be repeated up to
10,000 times or more (Cowman and Matsuoka 2005)
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synthesis pathway can then be divided into two distinct
pathways that synthesise the two building blocks of HA,
glucuronic acid and N-acetylglucosamine (Fig. 2).
In the first set of reactions, a-phosphoglucomutase
(pgm) converts glucose-6-phosphate to glucose-1-phos-
phate before a phosphate group from UTP is transferred to
glucose-1-phosphate by UDP-glucose pyrophosphorylase
(hasC) to produce UDP-glucose. Finally, UDP-glucose is
oxidised by UDP-glucose dehydrogenase (hasB) to yield
the first HA precursor, UDP-glucuronic acid (UDP-
GlcUA). In the second set, glucose-6-phosphate is con-
verted to fructose-6-phosphate by phosphoglucoisomerase
(hasE). Once converted, fructose-6-phosphate is tagged
with an amido group transferred from a glutamine residue
via amidotransferase (glmS) to produce glucosamine-6-
phosphate and then is modified by mutase (glmM) to yield
glucosamine-1-phosphate. This intermediate is then
sequentially acetylated and phosphorylated by acetyl-
transferase and pyrophosphorylase, respectively (hasD) to
yield the second HA precursor, UDP-N-acetylglucosamine
(UDP-GlcNAc). Once the two precursors are synthesised,
hyaluronic acid/hyaluronan synthase (hasA) polymerises
the two components in an alternate manner to produce the
HA polymer. It is important to note that HA biosynthesis is
an energy-consuming process for the bacteria as several
intermediates are also used in cell wall biosynthesis, bio-
mass formation and lactate formation via glycolysis (Shah
et al. 2013).
HA synthase (HAS)
In general, for any bacterium to synthesise HA capsule, the
HAS gene must be present as it is needed to polymerize
UDP-sugar precursors into HA. The hasA was first isolated
from S. pyogenes from Group A Streptococcus (GAS) and
it was shown to have the capability to direct HA capsule
biosynthesis in acapsular mutants as well as heterologous
bacteria such as E. coli and Enterococcus faecalis
(DeAngelis et al. 1993). Since then, other HA synthase
(HAS) related genes have been identified in other organ-
isms including Group C Streptococcus, algae, viruses and
vertebrates. Analysis of the primary sequence and pre-
dicted structural topologies have shown HAS enzymes
share many common features and have been divided into
two categories, (based on similarities and differences in
amino acid motifs, topology and mode of action) desig-































Fig. 2 Hyaluronic acid
biosynthetic pathway in S.
zooepidemicus. Glucose is first
converted by hexokinase to
form glucose-6-Phosphate
which then enters one of the two
distinct pathways to form UDP-
glucuronic acid (pgm, hasC and
hasB) or UDP-N-
acetylglucosamine (hasE, glmS,
glmM and hasD). These
precursors are then bound
together via the action of
hyaluronic acid synthase or
HAS (encoded by hasA in S.
zooepidemicus) to form
hyaluronic acid
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Class I HAS
The vast majority of HAS enzymes are Class I and have
been identified in Chlorella-like green algae virus (PBCV-
1), Group A and C Streptococci as well as vertebrates
(DeAngelis et al. 1993, 1997; Fraser et al. 1997). The key
features that define Class I HAS enzymes include:
1. Class I HAS enzymes have a single glycosyltrans-
ferase 2 (GT2) family module (a subset of common
catalytic residues among glycosyltransferase enzymes,
for their sugar addition reactions) and share amino acid
similarities in the central region of the protein
sequence;
2. This protein group is an integral membrane enzyme
with four to six predicted transmembrane domains
and one to two membrane domains are found in its
structure (Weigel 2002; Weigel and DeAngelis
2007);
3. These enzymes are thought to be associated with lipid
molecules (Fig. 3a) in order to synthesise and extrude
the HA molecules out of the cells to form either the
capsule or to be released into the extracellular space
(Tlapak-Simmons et al. 1999; Weigel 2015; Weigel
and DeAngelis 2007) and
4. Class I HAS adds UDP-sugars to the growing HA
polymer from the reducing end (Fig. 4) of the
growing HA chain (and some at the non-reducing
end for Xenopus laevis and algal virus HAS) (Weigel
2002).
Class II HAS
The only organism known to encode for a Class II HAS
enzyme, thus far, is P. multocida (DeAngelis et al. 1998).
The protein (known as pmHAS) has a number of key
features that distinguishes it from Class I HAS:
1. pmHAS is approximately twice the size of a Class I
HAS (972 versus 417–588 residues, respectively)
(DeAngelis et al. 1998);
2. pmHAS has two GT2 family modules (Weigel and
DeAngelis 2007);
3. pmHAS is a peripheral membrane protein that does not
necessarily require association with lipid bilayer and
transporters of cell membrane to synthesise HA;
4. pmHAS consists of two independent catalytic domains
that are responsible for GlcNAc and GlcUA trans-
ferase activity (Fig. 3b) (Jing and DeAngelis 2000);
and
5. pmHAS adds UDP-sugars to the growing HA polymer
from the non-reducing end (DeAngelis 1999) (Fig. 4)
pmHAS has been expressed and successfully synthe-
sised HA in a number of bacterial species, including E. coli
(Liu et al. 2011; Mao and Chen 2007; Mao et al. 2009).
Since then this enzyme has become a focal point for cell-
free HA production as its truncated form (pmHAS1-703)
does not need to be bound to a membrane in order to
synthesise HA (DeAngelis et al. 1998; Jing and DeAngelis
2003, 2004; Kooy et al. 2013).
Table 1 Characteristics and
features of Class I and Class II
HA synthases
Feature Class I Class II
Source organisms Streptococci, amphibian, mammal,
yeast, virus
Pasteurella multocida
Ability to be expressed as soluble
active protein
No (must be associated with cell
membrane)
Yes (amino acid residues 1–703)
Number of GT2 module 1 2
HA chain growth At reducing end—Streptococcus,
humans and mice
At non-reducing end—Xenopus
laevis and algal virus
At non-reducing end
Topology of the protein Multiple membrane associated
domains throughout the whole
protein
Two catalytically independent
domains, A1 and A2 attached to
membrane via C-terminal region
Intrinsic polymerization Processive Non-processive
Size (amino acids) 417–588 972
Primer for initiation of HA
synthesis?
No Yes







machinery (more studies needed
to confirm)
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HA market in healthcare industry
HA’s essential functions in the human eye, synovial fluid
of joints and in the epidermal layers, has led to consider-
able interest in developing new methods to successfully
synthesise and deliver HA. A recent market analysis report
predicted that as a consequence of an aging population and
an increase in osteoarthritis the global market for HA
visco-supplementation in humans alone was estimated to
be more than $2.5 billion by 2017 (MRG.Net 2013).
The first ever patented HA product, called Healon, was
obtained from rooster combs (Balazs 1979). This product
was an immediate success following its use as a
viscoelastic substance that acts to supplement and recover
the loss of vitreous body fluid during eye surgery. The
introduction of this non-inflammatory HA product has
since led to the development of other HA-based products
which are useful for biomedical and cosmetic applications.
The first ever single-injection HA viscosupplementation
product, Synvisc-One and produced by Genzyme, was
approved by the US Food and Drug Administration (FDA)
in 2009 and has since gained a lot of popularity due to its
convenience and effectiveness in relieving pain for
osteoarthritis in knee joints. Following this major break-
through, the demand for easy-to-use HA-based products
has escalated in other parts of the world including Europe
and the Asia-Pacific. Restylane, is the first HA-based der-
mal filler developed to correct moderate to severe wrinkles
and folds. This product is not only effective but it is also
widely used in more than 65 countries because of utilisa-
tion of production technology called NASHA (non-animal
stabilized HA) which eliminates the use of animal parts
during HA extraction (van Eijk and Braun 2007). Other
HA-based products that are being sold in the current
market are skin moisturizers, wound dressing materials (to
promote wound healing after surgery) (Kogan et al. 2007)
and polymeric scaffolds for controlled drug release and
tissue engineering (Allison and Grande-Allen 2006).
Current production of HA and potential concerns
Currently, industrial production of HA is based on either
HA extraction from animal tissues or via large-scale bac-
terial fermentation with genetically modified strains. These
processes are widely used and have been able to generate
HA products with molecular weights above 1 MDa (as
half-life of the molecule will increase and persist longer
while maintaining its physiological function), which is
desirable for biomedical and cosmetic use (Liu et al. 2011).
Extraction from animal tissue
Since the early 1930s when HA was first isolated from bovine
vitreous humor (Meyer andPalmer 1934), extraction ofHAhas
been widely carried out using other animal tissues including
human umbilical cord, rooster comb, and bovine synovial fluid.
HA derived from animal tissues have naturally high molecular
weights and the highest concentration ever reported was from
rooster combs which can reach up to 7500 lg hyaluronan/g of
that animal tissue (Fraser et al. 1997).
Today, although animal-derived HA still remains as an
important resource for most HA-based products, alternative
production processes have been sought for a number of
reasons. First, the extraction processes have always expe-






















Fig. 3 Schematic representation of HA biosynthesis in Class I and
Class II Hyaluronic Acid Synthases (HAS). a Class I HAS are integral
membrane proteins that catalyse the UDP-sugar addition to growing
HA chain and may transport the hydrophilic HA polymer across the
cell membrane of eukaryotes or Gram-positive bacteria. Lipid
molecules (yellow circles) facilitate the HAS activity which allows
it to direct HA translocation. b Class II HAS is a peripheral protein
that also catalyses HA elongation. This enzyme is a hybrid of two
glycosyltransferases that transfers GlcNAc-UDP and GlcUA-UDP at
the non-reducing end of the HA chain. It was suggested that this
protein may interact with other cell membrane proteins (capsular
polysaccharide transport protein–purple block) in order to translocate
HA across the cell membrane of Gram-negative bacteria (P.
multocida). Blue and red dots represent GlcUA and GlcNAc,
respectively. Orange triangle represents the UDP component of the
sugar
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conditions that comes with grinding, acid treatment, and
repeated extraction with organic solvents. This uncon-
trolled degradation technique greatly affects not only the
yield but also the polydispersity (range of sizes) of HA
(Boeriu et al. 2013). A second problem is that animal HA
may still be bound to cellular proteins including hyalur-
onidase, a HA-specific binding protein (Fraser et al. 1997).
These contaminant proteins are undesirable as there may be
a chance that these will illicit an immune response.
Moreover, there is a potential risk of contamination with
nucleic acids, prions (bovine) and viruses (avian) which
could result in the transmission of infectious disease
(Shiedlin et al. 2004). Finally, extracting HA from animal
tissues is costly as it takes considerable time to complete, is
labour intensive and requires large facilities that can
accommodate processes involved from collection of tissue
from the animal to extraction and purification of HA. As a
consequence of these technical and safety issues, biotech-
nological production of HA is seen as a preferred method
of producing HA.
Bacterial production of HA
Production of HA by bacterial fermentation has evolved
steadily over the past two decades. In its early stage of
development, Group A and C Streptococci that naturally
produced HA were grown in fermenters and HA was
purified. However, as these bacteria produce a number of
toxins, alternative bacteria were sought. Once the genes
that encode for the HA biosynthetic pathway were deter-
mined, a number of bacteria (Bacillus, Agrobacterium,
E. coli and Lactococcus) were genetically modified to
express these genes and produce HA. Subsequent work has
focused on optimization of culture media and cultivation
conditions (DeAngelis et al. 1993, 1998; Mao and Chen
2007; Wessels et al. 1991; Widner et al. 2005).
Currently, the Bacillus production system (B. subtilis) is
a well-characterized Gram-positive microorganisms (along
with Group A and C Streptococci) established as industrial
workhorses for the production of various products,
including HA (Novozymes). The expression constructs
UDP 











UDP UDP    + 




Class II HAS 
Class I HAS 
Fig. 4 Position of non-reducing
and reducing ends of a growing
HA chain. Polymerisation of
HA by Class I HAS occurs
whereby the UDP group present
at the reducing end of the HA
polysaccharide is released to
form a glycosidic bond between
the growing chain and the new
sugar-UDP (in this example
GlcUA-UDP would be added,
followed by GlcNAc-UDP).
Class II HAS adds new sugar-
UDPs to the non-reducing end
of the HA polysaccharide. The
HA growing chain remains
attached to the same UDP group
at the reducing end (throughout
the whole polymerisation
process) while subsequent new
sugar-UDPs are being added to
the non-reducing end. Yellow
line represents the glycosidic
bond formed between GlcUA
and GlcNAc
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utilizing hasA gene from S. equisimilis in combination with
overexpression of one or more of the three native B. sub-
tilis precursor genes (homologous to hasB, hasC and hasD
in Streptococci) were used. B. subtilis has highly developed
biosynthetic capacity and capability to grow in industrial
fermenters. Its system is free of exotoxins and endotoxins
and, consequently, many products produced in this organ-
ism have been awarded a GRAS (generally recognized as
safe) designation (Widner et al. 2005).
While production of HA is commonly observed in
Gram-positive bacteria, many Gram-negative bacteria,
such as E. coli do not produce HA, as they either lack key
enzymes of the biosynthetic pathway, or express compo-
nents of the pathway at very low levels. Most strains of
E. coli commonly used in laboratories, such as JM109, do
not synthesise HA for these reasons. If, however, UDP-
glucose dehydrogenase (kfiD) from E. coli K5 and HAS
(pmHAS) from P. multocida, are expressed, it is possible to
synthesise HA in E. coli strains such as JM109 (Mao et al.
2009). HA production was further enhanced in this system
when combined with supplementation of the media with
glucose and glucosamine (precursors of HA) (Fig. 5),
during the induction process, with yields as high as 3.8 g/L
and maximal molecular weight of 1.5 MDa.
Cell-free production of HA (in vitro system)
While bacterial expression systems can produce HA in
small scale fermenters, in larger systems the production of
HA increases the viscosity of the media resulting in poor
mixing and low oxygen mass transfer rate, thus often yields
greater than 6–7 g/L are difficult to achieve (Liu et al.
2011). High polydispersity of HA produced in bacterial
fermentation also remains a challenge as production of
narrow polydispersity (or ideally, monodisperse) appears to
be highly dependent on the culture conditions. Finally, as is
the case for animal sources of HA, the bacterial cell itself
can act as a source of contamination (nucleic acids, HA
binding proteins, toxins, etc.) that may elicit an immune
response (Boeriu et al. 2013). Due to the limitations
associated with current mass production either from animal
or bacterial sources, cell-free production system (in vitro)
is seen as a desirable alternative.
Class I HAS family members are integral membrane
proteins and thus they are lipid-dependent. Isolation and
purification of this enzyme can be difficult as it requires
active detergent to solubilise the Class I HAS-membrane-
bound structure (De Luca et al. 1995; Tlapak-Simmons
et al. 2005). Without the close association with phospho-
lipid layer the function of Class I HAS enzyme would be
impaired. Thus while HA production is possible, it cannot
be achieved at a commercial scale.
The Class II HAS from P. multocida is amenable for cell
free HA production as the enzyme is a peripheral (not an
integral membrane protein) and does not need to be bound
to the membrane in order to function. Furthermore, dele-
tion studies have shown that removal of the membrane
domains (residues 704–972) generates a soluble enzyme
(known as pmHAS1-703) that retains the ability to syn-
thesise HA (Jing and DeAngelis 2000). Using this cell-free
Fructose-6-P Glucose-6-P Glucose 
kfiD gene 
To be supplemented












Fig. 5 Overview of
biosynthesis pathway for
recombinant HA production in
E. coli. In order to complete the
HA biosynthetic pathway in the
E. coli, expression of kfiD and
pmHAS genes along with
supplementation of glucosamine
(with glucose) into the culture
media are needed to allow the
bacteria to produce HA (Mao
et al. 2009)
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system it is possible to produce HA with high molecular
weight (*1–2 MDa) with low polydispersity (Jing and
DeAngelis 2004). The processivity of this HAS could be
controlled through the addition of HA oligomers (or
acceptors) to the reaction mixture, which circumvented the
rate-limiting step (formation of first glycosidic linkage)
allowing subsequent sugars to be added rapidly to the ends
of the oligomers, while the length of the HA polymer was
shown to be inversely proportional to the abundance of
oligomers. While high molecular weight HA can be
achieved using this system, the total yield of HA remains
very low.
Future perspective
Given the widespread cosmetic and medical applications of
HA, commercial interest in the rapid and safe production of
HA remains strong. Cell-free and/or non-pathogenic bac-
terial expression systems are considered to be safer alter-
natives to existing production systems, though as discussed
previously, are limited in their capacity to produce large
amounts of HA. While genes encoding for Class I or Class
II HAS enzymes cloned from diverse bacteria have suc-
cessfully synthesised HA in novel non-pathogenic host
bacteria such as E. coli, these enzymes have only ever been
expressed independently (Mao et al. 2009; Yu and Ste-
phanopoulos 2008). As both Class I and II HAS enzymes
extend the growing HA polymer in unique ways, in theory
these could act synergistically to produce HA. Such
experiments should be possible in E. coli or other
tractable bacterial expression systems.
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